The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs
Open accessAbstract
Some small molecules, often hits from screening, form aggregates in solution that inhibit many enzymes. In contrast, drugs are thought to act specifically. To investigate this assumption, 50 unrelated drugs were tested for promiscuous inhibition via aggregation. Each drug was tested against three unrelated model enzymes: beta-lactamase, chymotrypsin, and malate dehydrogenase, none of which are considered targets of these drugs. To be judged promiscuous, the drugs had to inhibit all three enzymes, do so in a time-dependent manner, be sensitive to detergent and to enzyme concentration, and form particles detectable by light scattering. Of the 50 drugs tested, 43 were nonpromiscuous by these criteria. Surprisingly, four of the drugs showed promiscuous, aggregation-based inhibition at concentrations below 100 microM: clotrimazole, benzyl benzoate, nicardipine, and delavirdine. Three other drugs also behaved as aggregation-based inhibitors, but only at high concentrations (about 400 microM). To investigate possible structure-activity relationships among promiscuous drugs, five analogues of the antifungal clotrimazole were studied. Three of these, miconazole, econazole, and sulconazole, were promiscuous but the other two, fluconazole and ketoconazole, were not. Using recursive partitioning, these experimental results were used to develop a model for predicting aggregate-based promiscuity. This model correctly classified 94% of 111 compounds-47 aggregators and 64 nonaggregators-that have been studied for this effect. To evaluate the model, it was used to predict the behavior of 75 drugs not previously investigated for aggregation. Several preliminary points emerge. Most drugs are not promiscuous, even at high concentrations. Nevertheless, at high enough concentrations (20-400 microM), some drugs can aggregate and act promiscuously, suggesting that aggregation may be common among small molecules at micromolar concentrations, at least in biochemical buffers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Ertl, P., Rohde, B., & Selzer, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000942e · Cited by 3,084
Simple Selection Criteria for Drug-like Chemical Matter
Muegge, I., Heald, S. L., & Brittelli, D. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015507e · Cited by 1,315
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,042
Self-citationIntegration of virtual and high-throughput screening
Bajorath, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd941 · Cited by 930
Hall, L. H., & Kier, L. B. (1995) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00028a014 · Cited by 763
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Reactive compounds and in vitro false positives in HTS
Rishton, G. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01083-0 · Cited by 351
Econazole: A Review of its Antifungal Activity and Therapeutic Efficacy
Heel, R. C., Brogden, R. N., Speight, T. M., & Avery, G. S. (1978) · Drugs · doi:10.2165/00003495-197816030-00001 · Cited by 296
Cited by
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
The role of natural product chemistry in drug discovery
Butler, M. S. (2004) · Journal of Natural Products · doi:10.1021/np040106y · Cited by 1,381
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Twenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Virtual Screening Strategies in Drug Discovery: A Critical Review
Lavecchia, A., & Giovanni, C. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990001 · Cited by 686
ESKAPEing the labyrinth of antibacterial discovery
Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., & Miller, A. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4572 · Cited by 608
Exploring biology with small organic molecules
Stockwell, B. R. (2004) · Nature · doi:10.1038/nature03196 · Cited by 470
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Recognizing Pitfalls in Virtual Screening: A Critical Review
Scior, T., Bender, A., Tresadern, G., Medina-Franco, J. L., Martínez-Mayorga, K., Langer, T., Cuanalo-Contreras, K., & Agrafiotis, D. K. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200528d · Cited by 438
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
A detergent-based assay for the detection of promiscuous inhibitors
Feng, B. Y., & Shoichet, B. K. (2006) · Nature Protocols · doi:10.1038/nprot.2006.77 · Cited by 429
Self-citationAn Aggregation Advisor for Ligand Discovery
Irwin, J. J., Duan, D., Torosyan, H., Doak, A. K., Ziebart, K. T., Sterling, T., Tumanian, G., & Shoichet, B. K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01105 · Cited by 418
Self-citationBiophysics in drug discovery: impact, challenges and opportunities
Renaud, J.-P., Chung, C.-W., Danielson, U. H., Egner, U., Hennig, M., Hubbard, R. E., & Nar, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.123 · Cited by 382
Fluorescence polarization assays in small molecule screening
Lea, W. A., & Simeonov, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.537322 · Cited by 379
Frye, S. V. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.296 · Cited by 375
Ilevbare, G. A., & Taylor, L. S. (2013) · Crystal Growth & Design · doi:10.1021/cg301679h · Cited by 366
In silico pharmacology for drug discovery: applications to targets and beyond
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707306 · Cited by 365
A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library
Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., & Austin, C. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061317y · Cited by 358
Self-citationJanssen, P. A. J., Lewi, P. J., Arnold, E., Daeyaert, F., de Jonge, M., Heeres, J., Koymans, L., Vinkers, M., Guillemont, J., Pasquier, E., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040840e · Cited by 347
Fragment-based lead discovery: leads by design
Carr, R. A. E., Congreve, M., Murray, C. W., & Rees, D. C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03511-7 · Cited by 343
Natural products and combinatorial chemistry: back to the future
Ortholand, J.-Y., & Ganesan, A. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.011 · Cited by 336
High-throughput assays for promiscuous inhibitors
Feng, B. Y., Shelat, A., Doman, T. N., Guy, R. K., & Shoichet, B. K. (2005) · Nature Chemical Biology · doi:10.1038/nchembio718 · Cited by 336
Self-citationInterpreting steep dose-response curves in early inhibitor discovery.
Shoichet, B. K. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm061103g · Cited by 304
Self-citationRecognizing and exploiting differences between RNAi and small-molecule inhibitors
Weiss, W. A., Taylor, S. S., & Shokat, K. M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio1207-739 · Cited by 283
Screening in a spirit haunted world
Shoichet, B. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.014 · Cited by 276
Self-citationLagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 266
FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects
Lagorce, D., Sperandio, O., Galons, H., Miteva, M. A., & Villoutreix, B. O. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-396 · Cited by 263
Introduction to Fragment-Based Drug Discovery
Erlanson, D. A. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_180 · Cited by 259
de Wispelaere, M., Du, G., Donovan, K. A., Zhang, T., Eleuteri, N. A., Yuan, J. C., Kalabathula, J., Nowak, R. P., Fischer, E. S., Gray, N. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11429-w · Cited by 237
Badapple: promiscuity patterns from noisy evidence
Yang, J. J., Ursu, O., Lipinski, C. A., Sklar, L. A., Oprea, T. I., & Bologa, C. G. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0137-3 · Cited by 103
Divergent modes of enzyme inhibition in a homologous structure-activity series.
Ferreira, R. S., Bryant, C., Ang, K. K. H., McKerrow, J. H., Shoichet, B. K., & Renslo, A. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9009229 · Cited by 88
Self-citationMachine learning models identify molecules active against the Ebola virus in vitro
Ekins, S., Freundlich, J. S., Clark, A. M., Anantpadma, M., Davey, R. A., & Madrid, P. (2015) · F1000Research · doi:10.12688/f1000research.7217.1 · Cited by 84
Malek, R., Arribas, R. L., Palomino-Antolin, A., Totoson, P., Demougeot, C., Kobrlova, T., Soukup, O., Iriepa, I., Moraleda, I., Diez-Iriepa, D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00937 · Cited by 45
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- Seidler, J., McGovern, S. L., Doman, T. N., & Shoichet, B. K.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2003-09-13
- Volume
- 46
- Issue
- 21
- Pages
- 4477-4486
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2154183412
- Cited by
- 476
- References
- 20
- FWCI
- 20.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.